{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    8,
    10,
    15,
    17,
    31,
    32,
    43
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 0.7,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_6",
        "affectedSection": "Protocol Title / Synopsis",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Evaluation of Axicabtagene Ciloleucel versus Standard of Care (SOC) in Phase 3 randomized setting for r/r DLBCL."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_6",
        "affectedSection": "Section 10.5.2 - Efficacy Interim Analysis",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Implementation of a planned interim futility analysis reviewed by the DSMB."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_6",
        "reasonText": "To compare efficacy and safety of CAR T-cell therapy against platinum-based salvage chemotherapy and ASCT in early relapsed/refractory patients.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_6",
        "reasonText": "Address the significant unmet need in patients resistant to first-line rituximab-based chemoimmunotherapy.",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_6",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.2.3.2",
        "beforeText": "Not explicitly provided in the provided text snippet for previous versions.",
        "afterText": "Target dose of 2 x 10^6 anti-CD19 CAR T cells/kg; minimum of 1 x 10^6 anti-CD19 CAR T cells/kg; maximum flat dose of 2 x 10^8 for subjects > 100 kg.",
        "summary": "Defined specific dosing tiers and maximum flat dose for axicabtagene ciloleucel based on ZUMA-1 data."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_6",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "Synopsis - Study Design",
        "beforeText": "Not explicitly provided.",
        "afterText": "Randomization will be stratified by response to first-line therapy and second-line age-adjusted IPI (0 to 1 vs 2 to 3).",
        "summary": "Clarified the stratification factors for the randomization process."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_6",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.3.1",
        "beforeText": "Not explicitly provided.",
        "afterText": "SOC will consist of protocol-defined, platinum-based salvage combination chemotherapy (R-ICE, R-GDP, R-DHAP, or R-ESHAP).",
        "summary": "Specified the allowed standard of care chemotherapy regimens for the control arm."
      }
    ],
    "summary": {
      "impactCount": 2,
      "reasonCount": 2,
      "changeCount": 3
    }
  }
}